It's been a pretty wild ride for Alnylam (Nasdaq:ALNY)
shareholders, even by the elevated standards of biotechnology. Once
thought to have the IP keys to one of the next great platform
technologies (RNA interference), the stock was hammered down over
several years as multiple Big Pharma companies chose to back away from
the technology and partnerships with Alnylam. Since late 2011, though,
it's been a return to investor love for Alnylam as positive clinical
data and a bull market in biotech has fueled a fourfold rise in the
shares.
Please follow the link to continue:
http://www.investopedia.com/stock-analysis/052813/alnylam-basking-orphan-drug-attention-alny-alxn-isis-pfe-amgn.aspx
No comments:
Post a Comment